Coronary Disease in Diabetes: Diabetic Patients Have Much Greater Plaque Progression

Patients with diabetes mellitus experience significantly greater plaque progression, particularly regarding adverse plaque. Male sex and baseline plaque volume >75% were identified as independent risk factors for plaque progression; the latter actually tripled the risk.

This study with tomographic follow-up sought to determine the rate and extent of plaque progression, changes in plaque features, and clinical predictors of plaque progression in patients with diabetes.

 

A total of 1602 patients (age 61.3 ± 9.0 years; 60.3% men) assessed with coronary computed tomography angiography over a period of at least 24 months were enrolled in the PARADIGM (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) trial.


Read also: Silent Diabetes Is the New Stealthy Enemy.


Study endpoints were changes in plaque features and plaque progression in diabetic patients compared with non-diabetic patients, as assessed by serial coronary computed tomography angiography. Plaque progression was defined as any plaque volume increase between baseline and follow-up.

 

As expected, diabetes was a risk factor for plaque progression (odds ratio [OR]: 1.526; 95% confidence interval [CI]: 1.100 to 2.118; p = 0.011). Changes in plaque volume and necrotic core volume were significantly greater in patients with diabetes.

 

Spotty calcification in nodules, positive remodeling, and burden of low-attenuation (soft) plaque were also more frequent in diabetic patients.


Read also: Does a Combination of Diabetes and Acute Coronary Syndrome Change the Revascularization Strategy?


Independent risk factors for plaque progression in patients with diabetes were male sex (OR: 1.4; p = 0.048) and plaque volume at baseline above 75% (OR: 3.1; p = 0.001).

 

The PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study, published in the 2011 New England Journal of Medicine (NEJM) article A Prospective Natural-History Study of Coronary Atherosclerosis, had included patients with acute coronary syndromes and, after treating the culprit artery, assessed all vessels through intravascular ultrasound (IVUS), looking for clues that might predict which non-culprit vessel plaque might trigger future events. Results were similar in aspects such as plaque volume; however, PROSPECT researchers highlighted a combination of characteristics (plaque volume plus thin-cap fibroatheromas plus minimal luminal area >4.0 mm2).

 

We still have not found the correct risk characteristics so as to apply prophylaxis to functionally non-significant plaque, but clues abound.

 

Conclusion

Diabetic patients experience much greater plaque progression, which is particularly significant as regards adverse plaque. Male sex and, fundamentally, baseline plaque volume >75% were independent predictors of progression.

 

Original title: Natural History of Diabetic Coronary Atherosclerosis by Quantitative Measurement of Serial Coronary Computed Tomographic Angiography Results of the PARADIGM Study (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging).

Reference: Ung Kim et al. J Am Coll Cardiol Img 2018; online before print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...